Trial · NCT01177709
Metformin for Weight Loss in Schizophrenia
NCT01177709, Not applicable, Terminated, Nathan Kline Institute for Psychiatric Research; results first posted 2017-02-07
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Metformin for Weight Loss in Schizophrenia. Trials, record NCT01177709. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01177709
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Metformin for Weight Loss in Schizophrenia
- NCT number
- NCT01177709
- Status
- Terminated
- Phases
- Not applicable
- Enrollment
- 12 participants, actual
- Lead sponsor
- Nathan Kline Institute for Psychiatric Research
- Conditions
- Schizophrenia, Obesity
- Interventions
- Metformin
- First posted
- 2010-08-09
- Last updated
- 2017-09-01
- Results first posted
- 2017-02-07
- Limitations and caveats
This is an open non-blinded study in a small number of subjects. However, it is unlikely that outcomes measures of weight, glucose, and insulin, would have been likely to be affected by non-blinding of subjects and investigators. .
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Weight (wt) in Pounds (Lbs).. | baseline, 4 weeks, 8 weeks, 12 weeks | Patients weight in pounds |
| Secondary | Glucose Levels | baseline, 4 weeks, 8 weeks, 12 weeks | Fasting glucose |
| Secondary | Insulin Level | baseline, 4 weks, 8 weeks, 12 weeks | fasting serum insulin uIU/ml. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Weight (wt) in Pounds (Lbs).. | baseline, 4 weeks, 8 weeks, 12 weeks | weight(wt) in pounds(lbs) | MEAN | |
| SECONDARY | Glucose Levels | baseline, 4 weeks, 8 weeks, 12 weeks | mg/dL | MEAN | |
| SECONDARY | Insulin Level | baseline, 4 weks, 8 weeks, 12 weeks | uIU/ml | MEAN |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Weight (wt) in Pounds (Lbs).. | Metformin | baseline wt lbs | 250.97 | Standard Error 11.52 | weight(wt) in pounds(lbs) |
| Weight (wt) in Pounds (Lbs).. | Metformin | 4 week wt lbs | 244.73 | Standard Error 10.84 | weight(wt) in pounds(lbs) |
| Weight (wt) in Pounds (Lbs).. | Metformin | 8 week wt lbs | 244.15 | Standard Error 10.06 | weight(wt) in pounds(lbs) |
| Weight (wt) in Pounds (Lbs).. | Metformin | 12 week wt lbs | 240.44 | Standard Error 9.22 | weight(wt) in pounds(lbs) |
| Glucose Levels | Metformin | basline glucose | 111.05 | Standard Error 12.83 | mg/dL |
| Glucose Levels | Metformin | week 4 glucose | 87.00 | Standard Error 2.95 | mg/dL |
| Glucose Levels | Metformin | week 8 glucose | 89.17 | Standard Error 2.17 | mg/dL |
| Glucose Levels | Metformin | week 12 gluocse | 94.25 | Standard Error 3.85 | mg/dL |
| Insulin Level | Metformin | baseline insulin | 11.18 | Standard Error 1.32 | uIU/ml |
| Insulin Level | Metformin | week 4 insulin | 11.53 | Standard Error 21.71 | uIU/ml |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Metformin | 12 | |
| Overall Study | COMPLETED | Metformin | 12 | |
| Overall Study | NOT COMPLETED | Metformin | 0 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | low serum sodium, | Renal and urinary disorders | Metformin | 1 | 12 | 1 |
| serious | penumonia | Respiratory, thoracic and mediastinal disorders | Metformin | 1 | 12 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Metformin | ||
| Total, other adverse events | Metformin | 0 | 12 |
| Total, serious adverse events | Metformin | 2 | 12 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01177709
GET https://conductscience.org/api/trials/v1/NCT01177709/registered